Suppr超能文献

与成人生长激素缺乏高/中/低可能性相关的医疗费用:一项医疗保健理赔数据库分析

Medical Costs Associated with High/Moderate/Low Likelihood of Adult Growth Hormone Deficiency: A Healthcare Claims Database Analysis.

作者信息

Yuen Kevin C J, Blevins Lewis S, Clemmons David R, Faurby Mads, Hoffman Andrew R, Kelepouris Nicky, Kerr Janice M, Tarp Jens Magelund, Fleseriu Maria

机构信息

Barrow Pituitary Center, Barrow Neurological Institute and St. Joseph's Hospital and Medical Center, University of Arizona College of Medicine and Creighton School of Medicine, Phoenix, AZ, USA.

Department of Neurosurgery, University of California, San Francisco, CA, USA.

出版信息

Clinicoecon Outcomes Res. 2024 Mar 8;16:133-147. doi: 10.2147/CEOR.S445495. eCollection 2024.

Abstract

PURPOSE

Adult growth hormone deficiency (AGHD) is often underdiagnosed and undertreated, leading to costly comorbidities. Previously, we developed an algorithm to identify individuals in a commercially insured US population with high, moderate, or low likelihood of having AGHD. Here, we estimate and compare direct medical costs by likelihood level.

PATIENTS AND METHODS

Retrospective, observational analysis using the Truven Health MarketScan database to analyze direct medical costs relating to inpatient and outpatient claims, outpatient prescription claims, medication usage, clinical utilization records, and healthcare expenditures. Patients were categorized into groups based on algorithmically determined likelihoods of AGHD. Likelihood groups were further stratified by age and sex. Trajectories of annual costs (USD) by likelihood level were also investigated.

RESULTS

The study cohort comprised 135 million US adults (aged ≥18 years). Individuals ranked as high-likelihood AGHD had a greater burden of comorbid illness, including cardiovascular disease and diabetes, than those ranked moderate- or low-likelihood. Those in the high-likelihood group had greater mean total direct medical monthly costs ($1844.51 [95% confidence interval (CI): 1841.24;1847.78]) than those in the moderate- ($945.65 [95% CI: 945.26;946.04]) and low-likelihood groups ($459.10 [95% CI: 458.95;459.25]). Outpatient visits accounted for the majority of costs overall, although cost per visit was substantially lower than for inpatient services. Costs tended to increase with age and peaked around the time that individuals were assigned a level of AGHD likelihood. Total direct medical costs in individuals with a high likelihood of AGHD exceeded those for individuals with moderate or low likelihood.

CONCLUSION

Understanding the trajectory of healthcare costs in AGHD may help rationalize allocation of healthcare resources.

摘要

目的

成人生长激素缺乏症(AGHD)常常诊断不足且治疗不充分,从而导致代价高昂的合并症。此前,我们开发了一种算法,用于识别美国商业保险人群中AGHD可能性高、中或低的个体。在此,我们按可能性水平估算并比较直接医疗费用。

患者与方法

使用Truven Health MarketScan数据库进行回顾性观察分析,以分析与住院和门诊理赔、门诊处方理赔、药物使用、临床利用记录及医疗保健支出相关的直接医疗费用。根据算法确定的AGHD可能性将患者分为不同组。可能性组再按年龄和性别进一步分层。还研究了按可能性水平划分的年度费用(美元)轨迹。

结果

研究队列包括1.35亿美国成年人(年龄≥18岁)。与AGHD可能性为中或低的个体相比,可能性为高的个体合并症负担更重,包括心血管疾病和糖尿病。高可能性组的平均每月直接医疗总费用(1844.51美元[95%置信区间(CI):1841.24;1847.78])高于中可能性组(945.65美元[95%CI:945.26;946.04])和低可能性组(459.10美元[95%CI:458.95;459.25])。总体而言,门诊就诊占费用的大部分,尽管每次就诊费用远低于住院服务。费用往往随年龄增加而上升,并在个体被确定为AGHD可能性水平时达到峰值。AGHD可能性高的个体的直接医疗总费用超过了可能性为中或低的个体。

结论

了解AGHD患者的医疗费用轨迹可能有助于合理分配医疗资源。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee93/10929649/a2af5f7f4c5b/CEOR-16-133-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验